Coherus BioSciences, Inc. (CHRS)
Largest Insider Buys in Sector
CHRS Stock Price History Chart
CHRS Stock Performance
About Coherus BioSciences, Inc.
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab …
Insider Activity of Coherus BioSciences, Inc.
Over the last 12 months, insiders at Coherus BioSciences, Inc. have bought $0 and sold $0 worth of Coherus BioSciences, Inc. stock.
On average, over the past 5 years, insiders at Coherus BioSciences, Inc. have bought $49,668 and sold $7.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,700 shares for transaction amount of $49,668 was made by Stilwell McDavid (Chief Financial Officer) on 2021‑06‑09.
List of Insider Buy and Sell Transactions, Coherus BioSciences, Inc.
| 2023-11-22 | Sale | President & CEO | 223,100 0.2098% | $2.02 | $449,770 | +2.49% | ||
| 2021-10-15 | Sale | Chief Financial Officer | 3,507 0.0045% | $16.80 | $58,919 | -30.65% | ||
| 2021-09-29 | Sale | director | 286,076 0.3546% | $16.12 | $4.61M | -26.09% | ||
| 2021-09-28 | Sale | director | 48,329 0.0622% | $17.17 | $829,809 | -27.59% | ||
| 2021-09-27 | Sale | director | 100,150 0.1287% | $18.06 | $1.81M | -30.86% | ||
| 2021-06-09 | Chief Financial Officer | 3,700 0.0049% | $13.42 | $49,668 | +0.96% | |||
| 2021-06-08 | Sale | President & CEO | 31,054 0.0411% | $13.56 | $421,229 | +0.59% | ||
| 2021-03-09 | Sale | Chief Scientific Officer | 114,240 0.1583% | $16.25 | $1.86M | -9.44% | ||
| 2021-03-05 | Sale | Chief Operating Officer | 26,649 0.0357% | $15.46 | $412,065 | -7.55% | ||
| 2021-02-17 | Sale | Chief Operating Officer | 2,488 0.0034% | $17.45 | $43,418 | -13.71% | ||
| 2021-02-01 | Sale | Chief Financial Officer | 7,402 0.0124% | $21.55 | $159,513 | -13.35% | ||
| 2021-01-25 | Sale | Chief Financial Officer | 46,144 0.0647% | $19.95 | $920,736 | -21.18% | ||
| 2021-01-19 | Sale | Chief Operating Officer | 2,500 0.0034% | $17.94 | $44,852 | -13.26% | ||
| 2020-12-17 | Sale | Chief Operating Officer | 2,500 0.0034% | $17.51 | $43,780 | -10.94% | ||
| 2020-12-10 | Sale | Chief Scientific Officer | 17,626 0.0246% | $18.05 | $318,066 | -11.68% | ||
| 2020-12-09 | Sale | Chief Scientific Officer | 49,512 0.0685% | $18.24 | $903,084 | -13.28% | ||
| 2020-12-07 | Sale | Chief Operating Officer | 8,791 0.0122% | $18.42 | $161,896 | -13.80% | ||
| 2020-12-04 | Sale | Chief Operating Officer | 49,000 0.0675% | $18.85 | $923,694 | -16.42% | ||
| 2020-12-03 | Sale | Chief Operating Officer | 49,756 0.0692% | $18.67 | $929,079 | -14.87% | ||
| 2020-11-18 | Sale | Chief Operating Officer | 4,283 0.006% | $18.00 | $77,094 | -11.09% |
Insider Historical Profitability
| LILLY ELI & CO | 3042019 2.6403% | $1.40 | 1 | 0 | +82.59% | |
| Stilwell McDavid | Chief Financial Officer | 31611 0.0274% | $1.40 | 1 | 1 | +0.96% |
| HEALY JAMES | director | 0 0% | $1.40 | 1 | 8 | +82.59% |
Institutional Investor Ownership
| BlackRock | $26.84M | 9.79 | 11.23M | -6.99% | -$2.02M | <0.01 | |
| Helm Capital Management LLC | $24.86M | 9.07 | 10.4M | +2,531.53% | +$23.91M | 0.74 | |
| The Vanguard Group | $24.09M | 8.79 | 10.08M | -2.68% | -$664,080.62 | <0.0001 | |
| Temasek Holdings | $17.64M | 6.43 | 7.38M | 0% | +$0 | 0.1 | |
| Kohlberg Kravis Roberts | $7.26M | 2.65 | 3.04M | 0% | +$0 | 0.23 |